Tissue-targeting drug delivery platform using T cell receptors to treat inflammatory diseases with precision.
Eugit Therapeutics develops a tissue-targeting drug delivery platform designed to address non-specific drugs that cause toxicity and clinical trial failures in tissue-specific inflammatory diseases. The platform uses T cell receptors to deliver drugs with precision to diseased tissues, enhancing safety and efficacy. Initial focus is on Inflammatory Bowel Disease, with plans to initiate clinical trials within two years. Co-founded by George Church, Professor at Harvard Medical School. Eugit Therapeutics is a product of Eugit Therapeutics.